Merck Makes a Deal as Dow Jones Drops on GDP Revisions

It's not putting a damper on deals as Merck sold its consumer health business for $14 billion.

May 6, 2014 at 1:34PM
Longview

The Dow Jones Industrial Average (DJINDICES:^DJI) is down after multiple economists revised their Q1 GDP growth estimates downward to negative following some weaker-than-expected economic releases. As of 1:20 p.m. EDT the Dow was down 83 points to 16,445. The S&P 500 (SNPINDEX:^GSPC) was down nine points to 1,876.

Just last week, analysts were expecting U.S. GDP growth of 1.1%. The Commerce Department surprised investors when in its first estimate of U.S. GDP said the economy only grew 0.1% in the first quarter. Now, multiple analysts expect that the U.S. economy shrank in the first quarter. Goldman Sachs cut its Q1 GDP forecast to -0.6% from -0.3%, and JPMorgan Chase cut its forecast to -0.8% from -0.4%. The reason is yesterday's trade deficit report, which showed that imports grew far more than many analysts had expected. Yet investors are still generally optimistic about the economy going forward and believe the bad Q1 was the result of the harsh winter.

The lowered forecast isn't putting a damper on big deals, however. This morning Merck (NYSE:MRK) announced it is selling its consumer health business to Bayer for $14.2 billion. Merck's consumer health business includes well-known brands such as Coppertone sunscreen, Claritin, Dr. Scholl's, and Lotrimin. The company announced it will use half the cash to buy back shares and then invest the rest in "those areas within its business that represent the highest potential growth opportunities, such as MK-3475, to augment the company's pipeline with external assets that can create value and to continue to provide an industry-leading return of capital to shareholders."

However, Merck stock is leading the Dow Jones downward today, as CEO Ken Frazier suggested that the company will not sell its animal health unit. In an interview with Forbes, Frazier said:

We're looking at strategic options for our animal health business, but my current point of view is that the business has scale it has strong growth prospects it's got a favorable macroeconomic outlook and a strong pipeline. So I would be looking for opportunities to build onto that business.

Merck has been refocusing itself around cancer drugs, cholesterol drugs, diabetes drugs, and vaccines, and as such it was reviewing its consumer health and animal health businesses for expansions or sales. Investors were hoping for a sale -- possible strategic acquirers include Sanofi or Eli Lilly -- or a spinoff, as Pfizer did last year with its animal health business Zoetis.

Foolish bottom line
There are still pockets of growth in the markets, but they are getting harder to find. While I continue believe the stock market is overvalued, opinions differ. But with the Federal Reserve committed to low interest rates and pumping money into the economy, who knows how high the market can go? One thing is for sure: It's getting harder and harder to find great companies at good prices.

One area of the market to find explosive growth
If you thought the iPod, the iPhone, and the iPad were amazing, just wait until you see this. One hundred of Apple's top engineers are busy building one in a secret lab. And an ABI Research report predicts 485 million of them could be sold over the next decade. But you can invest in it right now -- for just a fraction of the price of Apple stock. Click here to get the full story in this eye-opening new report.

Dan Dzombak can be found on Twitter @DanDzombak or on his Facebook page, DanDzombak. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers